Tandem Diabetes Care, Inc. announced the pricing of an upsized private placement of $265.0 million in 0.00% Convertible Senior Notes due 2032. The net proceeds of approximately $256.7 million will be used for capped call transactions and general corporate purposes, including potential acquisitions. The notes will mature on March 15, 2032, and are convertible into cash, common stock, or a combination thereof, at the company’s election, with an initial conversion price of approximately $36.99 per share.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
Tandem Diabetes Care, Inc. announced the pricing of an upsized private placement of $265.0 million in 0.00% Convertible Senior Notes due 2032. The net proceeds of approximately $256.7 million will be used for capped call transactions and general corporate purposes, including potential acquisitions. The notes will mature on March 15, 2032, and are convertible into cash, common stock, or a combination thereof, at the company’s election, with an initial conversion price of approximately $36.99 per share.